<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7046835</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.00287</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Perspective</subject></subj-group></subj-group></article-categories><title-group><article-title>Role of T Cells in Chikungunya Virus Infection and Utilizing Their Potential in Anti-Viral Immunity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Poh</surname><given-names>Chek Meng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/806322/overview"/></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Yi-Hao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/809678/overview"/></contrib><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Lisa F. P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/40302/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Singapore Immunology Network, Agency for Science, Technology and Research</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="aff2"><sup>2</sup><institution>National University of Singapore Graduate School for Integrative Sciences and Engineering, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="aff4"><sup>4</sup><institution>Institute of Infection and Global Health, University of Liverpool</institution>, <addr-line>Liverpool</addr-line>, <country>United Kingdom</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Allan Randrup Thomsen, University of Copenhagen, Denmark</p></fn><fn fn-type="edited-by"><p>Reviewed by: Philippe Gasque, Centre Hospitalier Universitaire de La R&#x000e9;union, France; Amarendra Pegu, National Institutes of Health (NIH), United States</p></fn><corresp id="c001">*Correspondence: Lisa F. P. Ng <email>lisa_ng@immunol.a-star.edu.sg</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><elocation-id>287</elocation-id><history><date date-type="received"><day>03</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Poh, Chan and Ng.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Poh, Chan and Ng</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Chikungunya virus (CHIKV) is an arthropod-borne alphavirus that causes hallmark debilitating polyarthralgia, fever, and rash in patients. T cell-mediated immunity, especially CD4<sup>+</sup> T cells, are known to participate in the pathogenic role of CHIKV immunopathology. The other T cell subsets, notably CD8<sup>+</sup>, NKT, and gamma-delta (&#x003b3;&#x003b4;) T cells, can also contribute to protective immunity, but their effect is not actuated during the natural course of infection. This review serves to consolidate and discuss the multifaceted roles of these T cell subsets during acute and chronic phases of CHIKV infection, and highlight gaps in the current literature. Importantly, the unique characteristics of skin-resident memory T cells are outlined to propose novel prophylactic strategies that utilize their properties to provide adequate, lasting protection.</p></abstract><kwd-group><kwd>chikungunya</kwd><kwd>T cells</kwd><kwd>immunopathology</kwd><kwd>vaccination</kwd><kwd>resident-memory T cells</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Agency for Science, Technology and Research<named-content content-type="fundref-id">10.13039/501100001348</named-content></funding-source><award-id rid="cn001">F00018</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="92"/><page-count count="8"/><word-count count="6156"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Chikungunya virus (CHIKV) belongs to the <italic>Togaviridae</italic> family and is transmitted to humans by arthropod vectors, primarily the <italic>Aedes aegypti</italic> and <italic>Ae. albopictus</italic> mosquitoes within an urban cycle (<xref rid="B1" ref-type="bibr">1</xref>). This alphavirus was first isolated from a patient from Tanzania in 1952 (<xref rid="B2" ref-type="bibr">2</xref>), but it spread only to few regions before mellowing down to sporadic outbreaks in the next 30 years (<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). It re-emerged in the last decade, starting from Kenya in 2004 (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Since then, it has broadened its geographical range to different regions of Africa, the R&#x000e9;union island, Asia, Europe, and the Americas (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>).</p><p>CHIKV-infected patients develop chikungunya fever (CHIKF), a febrile illness characterized with acute hallmark polyarthralgia, along with other disease manifestations like fever and maculopapular rash (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Symptoms usually manifest after 4&#x02013;7 days of incubation period (<xref rid="B3" ref-type="bibr">3</xref>). CHIKV infection has been shown by multiple studies to induce robust immune responses. Specifically, the type-I interferon (IFN)-associated pathways (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>), the recruitment of innate and adaptive immune cells to the site of infection (<xref rid="B22" ref-type="bibr">22</xref>), and the development of protective antibodies for virus resolution (<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>), has been shown to contribute significantly to the self-limiting nature of CHIKF. Although CHIKV-induced symptoms usually resolve in patients within 2 weeks (<xref rid="B16" ref-type="bibr">16</xref>), ~30&#x02013;40% of these patients go on to develop chronic arthritis, which can be due to inefficient viral clearance, or persistent immune response in patients (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B18" ref-type="bibr">18</xref>).</p><p>Host innate and adaptive immunity have multifaceted roles in CHIKV infection. While innate immunity in response to CHIKV infection has been well-studied (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B30" ref-type="bibr">30</xref>), the functions of adaptive components, such as T cells and their myriad associated roles remain less defined. Recent studies have started to show that CHIKV-specific T cells and antibody response play significant roles in antiviral immunity, immunomodulation and pathology in CHIKV infection (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). A better comprehension of the roles each T cell subset play during CHIKV infection may aid in understanding how to control disease progression and immune-mediated pathology. This review illustrates the significance of T cells in the protection and immunopathogenesis of acute and chronic arthritogenic disease. We also provide alternative perspectives on the prophylactic and therapeutic potential of T cells against CHIKV.</p></sec><sec id="s2"><title>CD8<sup>+</sup> T Cells</title><p>CD8<sup>+</sup> T cells have contrasting effects on alphavirus infection. In humans, CD8<sup>+</sup> T cells express CD69, CD107a, granzyme B, and perforin during acute CHIKV infection (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>), markers associated with T cell activation. Studies have identified putative CD8 epitopes within the CHIKV genome in mice and humans (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Among these antigenic determinants, the non-structural proteins (nsP1-nsP4) contain a multitude of epitopes that can induce a robust immunological response. Only HLA-A24, B7, and B15 were predicted to express CD8 epitopes hidden within the capsid, E1 and E2 proteins (<xref rid="B35" ref-type="bibr">35</xref>). Despite the apparent abundance, only three HLA-A<sup>*</sup>0201 CD8 epitopes in CHIKV 6K protein were experimentally validated to trigger CD8 T cell response (<xref rid="B37" ref-type="bibr">37</xref>). The paucity of epitope validation highlights the inaccuracy of <italic>in silico</italic> modeling to predict epitope immunogenicity. Nevertheless, predicted epitopes require further testing to validate the sequences that are presented by different MHCs. Importantly, it remains unclear whether the recognition of CHIKV epitopes by CD8<sup>+</sup> T cells has a role to play in eliminating virus-infected cells. This knowledge gap is worth investigating and will open up avenues to employ them as mediators in future CHIKV vaccines.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>The list of conserved CD8 epitopes in CHIKV that was identified <italic>in silico</italic> by others and published in the literature were arranged according to the positions they occupy along the CHIKV proteome. The immunogenicity scores are determined through the Immune Epitope Database (IEDB) and plotted as shown. Of all the CD8 epitopes, only the three epitopes in the 6K region are experimentally validated.</p></caption><graphic xlink:href="fimmu-11-00287-g0001"/></fig><p>In mouse models, CD8<sup>+</sup> T cell numbers in the joints increased during acute CHIKV infection. However, they do not protect against CHIKV-associated pathologies as mice deficient in CD8<sup>+</sup> T cells still developed joint inflammation (<xref rid="B31" ref-type="bibr">31</xref>). This observation is in contrast to other findings whereby CD8 T cells play an active role in mediating viral clearance and disease resolution in mouse models of Ross River virus (RRV) (<xref rid="B38" ref-type="bibr">38</xref>) and Venezuela Equine Encephalomyelitis virus (VEEV) (<xref rid="B39" ref-type="bibr">39</xref>). CHIKV RNA could be detected in the footpad of mice at up to 16 weeks post-challenge, suggesting that chronic CHIKV infection could persist in the footpad (<xref rid="B40" ref-type="bibr">40</xref>). Persistent infection indicates that CHIKV epitopes could be continuously presented by antigen-presenting cells (APCs) to CD8<sup>+</sup> T cells, leading to sustained activation of T cell receptor. This will eventually cause CD8<sup>+</sup> T cell exhaustion and render them incapable of eliminating infected cells (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>), resulting in perpetual CHIKV infection. Indeed, the lower levels of CD8<sup>+</sup> T cells and their decreased expression of activated marker CD69 suggest an exhausted phenotype in chronic CHIKV patients (<xref rid="B33" ref-type="bibr">33</xref>). In chronic viral (e.g., LCMV and HIV) and parasitic (e.g., malaria) diseases, persistent infection causes prolonged activation of CD8<sup>+</sup> T cells, which eventually drives them to exhaustion and become unresponsive. This condition happens through, mostly but not limited to, the programmed death-1 signaling axis (<xref rid="B43" ref-type="bibr">43</xref>&#x02013;<xref rid="B46" ref-type="bibr">46</xref>). The shutdown of exhausted CD8<sup>+</sup> T cell function allows pathogens to remain established, cascading into a vicious cycle of a further immune shutdown and more persistent infection. Given that CHIKV infection is shown to persist in infected mice and individuals (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B40" ref-type="bibr">40</xref>), the CHIKV-specific CD8<sup>+</sup> T cells may become exhausted and become incapable of controlling the infection. Targeting this pathway to reverse the exhaustion in CD8<sup>+</sup> T cells has been demonstrated to eliminate chronic malaria infection in a mouse model (<xref rid="B47" ref-type="bibr">47</xref>), thus indicating that this is another potential avenue to treat chronic CHIKV infection.</p></sec><sec id="s3"><title>CD4<sup>+</sup> T Cells</title><p>Activated CD4<sup>+</sup> T cells have been well-documented to play an essential role in the pathogenesis of CHIKV-induced joint swelling (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Our laboratory has comprehensively proven this through multiple methods. Mice depleted of CD4<sup>+</sup> T cells do not develop joint pathology when challenged with CHIKV. Concordantly, the use of fingolimod, which blocks lymphocytes from exiting the lymphoid organs, also reduces joint pathology in CHIKV infected mice. In addition, TCR<sup>&#x02212;/&#x02212;</sup> mice, which lack T cells, do not develop joint swelling when challenged (<xref rid="B32" ref-type="bibr">32</xref>). Independently, another group showed that the administration of antibodies against CTLA-4, which binds to CTLA-4 receptors found on the cell surface of activated CD4<sup>+</sup> T cells, caused elimination of the latter and thereby reduced joint swelling in CHIKV-infected mice (<xref rid="B49" ref-type="bibr">49</xref>). Currently, there is no mouse model that develops the chronic arthralgia and arthritis as seen in chronic patients. Thus, it remains to be seen if the activated CD4<sup>+</sup> T cells are also responsible for the chronic phase of CHIKV infection.</p><p>Pathogenic CHIKV-specific CD4<sup>+</sup> T cells in CHIKV mouse models express T-bet and secrete IFN-&#x003b3;, markers that are associated with Th1 phenotype (<xref rid="B50" ref-type="bibr">50</xref>). These findings concur with another study, which shows higher levels of Th1-associated cytokines in the sera of CHIKV-infected patients (<xref rid="B34" ref-type="bibr">34</xref>). Although this drives IFN-&#x003b3; production during infection, the antiviral effects of IFN-&#x003b3; are unable to block CHIKV replication in virus-infected cells due to CHIKV interference with downstream JAK-STAT signaling (<xref rid="B51" ref-type="bibr">51</xref>). These CD4<sup>+</sup> T cells, together with CD8<sup>+</sup> T cells, is detected in the joints of patients during the chronic phase of CHIKV infection (<xref rid="B34" ref-type="bibr">34</xref>). Two CHIKV CD4<sup>+</sup> epitopes have been identified in mouse models thus far, with the cognate CD4<sup>+</sup> T cells expressing IFN-&#x003b3; during CHIKV infection (<xref rid="B32" ref-type="bibr">32</xref>). Despite CD4<sup>+</sup> T cells being a cause of the pathogenic swelling accompanying CHIKV infection, they are also crucial in orchestrating the formation of CHIKV-specific antibody response. Dominant CHIKV-specific antibodies are of the isotype IgG2c (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B28" ref-type="bibr">28</xref>), and their production was severely impaired when CD4 T cells were absent (<xref rid="B28" ref-type="bibr">28</xref>).</p></sec><sec id="s4"><title>Regulatory T Cells</title><p>Among the heterogeneous CD4<sup>+</sup> T cell population, regulatory T cells (Tregs) can also contribute to the protection against CHIKV. Tregs are able to interact with APCs in the peripheral lymph nodes and bring about downregulation of costimulatory molecules in the latter (<xref rid="B52" ref-type="bibr">52</xref>). Thus, when the APCs present CHIKV epitopes to CD4<sup>+</sup> T cells, they become anergic instead and do not proliferate or migrate to the infected joints to cause joint swelling. However, the viral load in virus-infected mice was not affected by Tregs (<xref rid="B52" ref-type="bibr">52</xref>). Patients with acute and chronic CHIKV infections were shown to have lower levels of Treg, while recovered patients display Treg levels that are comparable to healthy controls (<xref rid="B53" ref-type="bibr">53</xref>). This finding concurs with the data from murine models, suggesting that Tregs prevent hyperactivation of pathogenic CD4<sup>+</sup> T cells, thereby controlling joint pathology.</p></sec><sec id="s5"><title>Natural Killer T Cells</title><p>The impact of natural killer T (NKT) cells in CHIKV infection is less well-understood. In patients, acute CHIKV infection resulted in an increase of NKT cells in the blood (<xref rid="B54" ref-type="bibr">54</xref>). These NKT cells were found to upregulate the expression of IFN-&#x003b3;, but not perforin. Although PBMCs from acute samples induced cytotoxicity in K562 cells during co-culture, it remains unclear if NKT cells account for the majority of the cytotoxicity effect (<xref rid="B54" ref-type="bibr">54</xref>). In chronic patients, NKT cell levels were significantly lower than healthy controls (<xref rid="B55" ref-type="bibr">55</xref>), although they still upregulated IFN-&#x003b3; expression. In contrast, the expression levels of IFN-&#x003b3; and TNF-&#x003b1; by NKT cells in convalescent patients are similar to that of healthy controls (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>).</p><p>In mice, levels of IFN-&#x003b3;-expressing NKT cell remain unchanged in CHIKV-infected mice, as compared to healthy controls (<xref rid="B48" ref-type="bibr">48</xref>). However, these cells accumulate in the spleens of mice that are co-infected with CHIKV and malaria parasites (<xref rid="B48" ref-type="bibr">48</xref>). This event is due to the increased expression of chemokines CXCL9 and CXCL10 in the spleens, which attract and retain lymphocytes that express cognate chemokine receptors. Since mouse and human NKT cells express CXCR3 (which recognizes CXCL9 and CXCL10), these cells are likely to be trapped in the spleen, preventing them from migrating to the peripheral joints (<xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>). Although this strategy of lymphocyte sequestration leads to decreased CHIKV immunopathology (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B49" ref-type="bibr">49</xref>), it is not clear how much does NKT cells contribute to this amelioration.</p></sec><sec id="s6"><title>Gamma-Delta (&#x003b3;&#x003b4;) T Cells</title><p>Gamma-delta T cells are reported to play a protective role against CHIKV infection (<xref rid="B59" ref-type="bibr">59</xref>). These cells do not affect CHIKV virus replication in the joints. Instead, their absence is associated with increased joint swelling and tissue damage in the infected mice. The absence of &#x003b3;&#x003b4; T cells were also linked to increased monocyte infiltration to the joints and increased levels of pro-inflammatory mediators CCL2, CXCL9, and IFN-&#x003b3; (<xref rid="B59" ref-type="bibr">59</xref>). Hence, the resulting pro-inflammatory milleu leads to more inflammatory cell infiltration and result in tissue damage that is observed during CHIKV infection. However, there is no information on the role of &#x003b3;&#x003b4; T cells in CHIKV patients. Thus, the extent of protection these cells offer in human settings remains unclear.</p></sec><sec id="s7"><title>Mobilizing T Cells Against CHIKV in Vaccine Design</title><p>The roles that each subset of T cells play in the joint swelling during CHIKV infection is illustrated in <xref ref-type="fig" rid="F2">Figure 2</xref>. Despite their participation in CHIKV immunopathology, they have the potential to be included as mediators of effective anti-CHIKV vaccine strategies. Although researchers have been investigating experimental vaccines against CHIKV, most of these still rely on antibodies to neutralize the viruses (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B60" ref-type="bibr">60</xref>&#x02013;<xref rid="B63" ref-type="bibr">63</xref>). Furthermore, some of the CHIKV vaccines have been demonstrated to protect against other alphaviruses, such as RRV (<xref rid="B19" ref-type="bibr">19</xref>) and O'nyong'nyong virus (ONNV) (<xref rid="B23" ref-type="bibr">23</xref>). In the RRV challenge study, the lowest effective dose (0.1 &#x003bc;g virus) that conferred complete protection (denoted as the absence of viremia) did not increase the antibody response against CHIKV. Full protection only happens when the authors increased the dosage to 10 &#x003bc;g (<xref rid="B19" ref-type="bibr">19</xref>). This observation suggests that T cells may be instrumental in conferring protection at the lower doses. However, vaccination with recombinant baculovirus expressing CHIKV envelope proteins caused aged mice (&#x0003e;18 months old) to become more susceptible to CHIKV infection (<xref rid="B62" ref-type="bibr">62</xref>), which was partly explained by the lower antibody titers in the aged mice. Although antigenic variations among CHIKV isolates are not prevalent currently, subtle changes in the CHIKV proteome was demonstrated to affect the neutralizing effect of pre-existing anti-CHIKV antibodies (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>). Thus, any mutation that results in reproductive-competent virus and yet abolishes antibody binding to CHIKV epitopes may result in future pandemic outbreaks.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Summary of the roles each T cell subset play during acute CHIKV infection. (1) When CHIKV-infected mosquitoes transmit the virus to its human host (or experimental infection in mice), CHIKV infects the surrounding cells and creates pro-inflammatory milleu in the joints. (2) This serves to attract monocytes and NKT cells to the joints, which exacerbates the inflammation by secreting pro-inflammatory cytokines and chemokines, thereby potentiating the chemoattraction of other immune cells to the infection site. (3) The APCs that engulfs CHIKV antigens travel to lymphoid organs, present CHIKV epitopes to CD4 and CD8 T cells and activate them. Activated CD4 T cells then trigger CHIKV-specific B cells to develop antibodies that can neutralize the virus. Treg cells may also interact with APCs that ultimately lead to anergy in CHIKV-specific CD4 T cells. (4) Proliferating CD4 and CD8 T cells migrate to the swollen joints and contribute to the inflammation through IFN-&#x003b3; secretion. Although not directly demonstrated, CHIKV-specific CD4 and CD8 T cells may recognize infected endothelial cells at the site of infection, leading to disruption of the barrier and worsens joint swelling.</p></caption><graphic xlink:href="fimmu-11-00287-g0002"/></fig></sec><sec id="s8"><title>Utilizing Skin Resident Memory T Cells to Confer Pan-Alphavirus Immunity</title><p>The notion of inducing CHIKV-specific memory T cells as mediators of protection is attractive as T cell epitopes are generally better conserved than B cell antigens, mitigating the risk of immune escape through antigenic variations (<xref rid="B66" ref-type="bibr">66</xref>&#x02013;<xref rid="B69" ref-type="bibr">69</xref>). Of the memory T cells, tissue-resident memory T cells (TRMs) are a unique subset of cells that is distinct from conventional memory T cells, in that the former dwell at the peripheral organs (<xref rid="B70" ref-type="bibr">70</xref>&#x02013;<xref rid="B73" ref-type="bibr">73</xref>). The latter either reside in the lymphoid organs (central memory T cells) or recirculate in the body (effector memory T cells) (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>). Thus, TRMs could function as adaptive immune cells that act as first-line responders at the site of infection (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B76" ref-type="bibr">76</xref>). Putative CHIKV-specific skin TRMs can be well-positioned to react to CHIKV-infected cells at the feeding site by virus-infected mosquitos during a blood meal.</p><p>Establishment of TRMs in the skin begins when clonally expanded T cells migrate from lymphoid organs to the skin. Some of these skin-homing T cells remain in place and develop into skin TRMs (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). Vaccination leads to the widespread establishment of TRMs throughout the body, not only at the vaccination site (<xref rid="B78" ref-type="bibr">78</xref>). Thus, it is highly plausible that one can generate CHIKV-specific skin TRMs through vaccination at the skin. Interestingly, effector T cells were reported to migrate to all parts of the skin instead of accumulating only at the site of the infection or vaccination (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>). This phenomenon occurs due to the presence of E-selectin, ICAM-1 and other chemokines that are expressed by post-capillary venules at low levels throughout the skin (<xref rid="B81" ref-type="bibr">81</xref>). Hence, the resulting skin TRMs generated can protect against CHIKV infection from anywhere, regardless of where the virus-infected mosquitoes choose to probe and release the virus into the host.</p><p>In the event where CHIKV penetrates the skin barrier and infect the surrounding cells during blood feeding by mosquitoes, CHIKV-specific skin resident memory T cells can recognize virus-infected cells quickly. This identification leads to rapid coordination of the anti-CHIKV immune responses and leads to the elimination of virus-infected cells before the disease is established (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Moreover, CHIKV exposure should further boost pre-existing anti-CHIKV immune response and lead to the accumulation of more CHIKV-specific skin resident memory T cells (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>). Over time, repeated exposure of CHIKV should lead to further CHIKV-specific skin TRM accumulation all over the skin, with no establishment of CHIKV pathology.</p><p>The geographical range of mosquitoes that transmit the alphaviruses is projected to increase in the future due to climate change (<xref rid="B84" ref-type="bibr">84</xref>). Moreover, CHIKV shares some homology with other alphaviruses with the potential to cause unprecedented outbreaks (<xref rid="B85" ref-type="bibr">85</xref>&#x02013;<xref rid="B89" ref-type="bibr">89</xref>). This shift may ultimately lead to the spread of CHIKV and other alphaviruses and cause future epidemics. However, as depicted by Roundy et al. (<xref rid="B90" ref-type="bibr">90</xref>) and Powers et al. (<xref rid="B91" ref-type="bibr">91</xref>), the close homology between CHIKV and other viruses within the family of alphaviruses suggest that they may share conserved epitopes that can induce T cell responses. Hence, some of the CHIKV-specific memory T cells can have the potential to target other alphaviruses and eliminate them. This knowledge may lead to the development of pan-alphavirus vaccines that are effective in preventing sudden alphavirus outbreaks, such as the spike in deaths from Eastern Equine Encephalomyelitis Virus (EEEV) in the United States in 2019, which is becoming endemic in the United States (<xref rid="B92" ref-type="bibr">92</xref>).</p></sec><sec id="s9"><title>Concluding Remarks</title><p>The re-emergence of CHIKV underscores the need for effective vaccine strategies to prevent further global CHIKV dissemination. In immunological na&#x000ef;ve individuals, CHIKV infection puts them at risk of having their immune system manipulated toward CHIKV pathology and virus persistence. An optimal vaccine against CHIKV invokes not only humoral response, but more importantly, localized CHIKV-specific, cell-mediated immunity at the skin, and yet avoids the induction of CHIKV-mediated immunopathology that is associated with pathogenic CD4 T cells. By inducing anti-CHIKV TRMs at the skin before infection strikes, they can rapidly clear the virus before it disseminates and triggers the associated immunopathology. Besides, anti-CHIKV TRMs have the potential to react to more conserved CHIKV epitopes (which may also be conserved in closely related alphaviruses) and the immunity buildup increases with each natural infection, providing a robust, potent immunity against CHIKV, and possibly other alphaviruses.</p></sec><sec id="s10"><title>Author Contributions</title><p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p><sec><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This study was funded by SIgN, Agency for Science, Technology and Research (A<sup>*</sup>STAR) core grant (Grant number F00018).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>E</given-names></name></person-group>. <article-title>The alphaviruses: gene expression, replication, and evolution</article-title>. <source>Microbiol Rev</source>. (<year>1994</year>) <volume>58</volume>:<fpage>491</fpage>&#x02013;<lpage>562</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.58.3.491-562.1994</pub-id><?supplied-pmid 7968923?><pub-id pub-id-type="pmid">7968923</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lumsden</surname><given-names>W</given-names></name></person-group>
<article-title>An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952&#x02013;1953 II. general description and epidemiology</article-title>. <source>T Roy Soc Trop Med H</source>. (<year>1955</year>) <volume>49</volume>:<fpage>33</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/0035-9203(55)90081-X</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Albert</surname><given-names>ML</given-names></name></person-group>. <article-title>Biology and pathogenesis of chikungunya virus</article-title>. <source>Nat Rev Microbiol</source>. (<year>2010</year>) <volume>8</volume>:<fpage>491</fpage>&#x02013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2368</pub-id><?supplied-pmid 20551973?><pub-id pub-id-type="pmid">20551973</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staples</surname><given-names>EJ</given-names></name><name><surname>Breiman</surname><given-names>RF</given-names></name><name><surname>Powers</surname><given-names>AM</given-names></name></person-group>. <article-title>Chikungunya fever: an epidemiological review of a re-emerging infectious disease</article-title>. <source>Clin Infect Dis</source>. (<year>2009</year>) <volume>49</volume>:<fpage>942</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1086/605496</pub-id><?supplied-pmid 19663604?><pub-id pub-id-type="pmid">19663604</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimmannitya</surname><given-names>S</given-names></name><name><surname>Halstead</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Margiotta</surname><given-names>M</given-names></name></person-group>. <article-title>Dengue and chikungunya virus infection in man in Thailand, 1962&#x02013;1964. I. observations on hospitalized patients with hemorrhagic fever</article-title>. <source>Am J Trop Med Hygiene</source>. (<year>1969</year>) <volume>18</volume>:<fpage>954</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.1969.18.954</pub-id><?supplied-pmid 5355242?><pub-id pub-id-type="pmid">5355242</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaikruea</surname><given-names>L</given-names></name><name><surname>Charearnsook</surname><given-names>O</given-names></name><name><surname>Reanphumkarnkit</surname><given-names>S</given-names></name><name><surname>Dissomboon</surname><given-names>P</given-names></name><name><surname>Phonjan</surname><given-names>R</given-names></name><name><surname>Ratchbud</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Chikungunya in Thailand: a re-emerging disease?</article-title>
<source>Southeast Asian J Trop Med Pub Health</source>. (<year>1997</year>) <volume>28</volume>:<fpage>359</fpage>&#x02013;<lpage>64</lpage>. <?supplied-pmid 9444021?><pub-id pub-id-type="pmid">9444021</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padbidri</surname><given-names>V</given-names></name><name><surname>Gnaneswar</surname><given-names>T</given-names></name></person-group>. <article-title>Epidemiological investigations of chikungunya epidemic at Barsi, Maharashtra state, India</article-title>. <source>J Hygiene Epidemiol Microbiol Immunol</source>. (<year>1979</year>) <volume>23</volume>:<fpage>445</fpage>&#x02013;<lpage>51</lpage>. <?supplied-pmid 575900?><pub-id pub-id-type="pmid">575900</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendis</surname><given-names>N</given-names></name></person-group>. <article-title>Epidemiology of dengue-like fever in Ceylon</article-title>. <source>Ceylon Med J</source>. (<year>1967</year>) <volume>12</volume>:<fpage>67</fpage>&#x02013;<lpage>74</lpage>. <?supplied-pmid 5588663?><pub-id pub-id-type="pmid">5588663</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munasinghe</surname><given-names>D</given-names></name><name><surname>Amarasekera</surname><given-names>P</given-names></name><name><surname>Fernando</surname><given-names>C</given-names></name></person-group>. <article-title>An epidemic of dengue-like fever in Ceylon (chikungunya&#x02013;a clinical and haematological study</article-title>. <source>Ceylon Med J</source>. (<year>1966</year>) <volume>11</volume>:<fpage>129</fpage>&#x02013;<lpage>42</lpage>. <?supplied-pmid 5984948?><pub-id pub-id-type="pmid">5984948</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Retuya</surname><given-names>T</given-names></name><name><surname>Ting</surname><given-names>D</given-names></name><name><surname>Dacula</surname><given-names>B</given-names></name><name><surname>Lanada</surname><given-names>J</given-names></name><name><surname>Jr</surname><given-names>RV</given-names></name><name><surname>Hugo</surname><given-names>C</given-names></name><name><surname>Ogayon</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Chikungunya fever outbreak in an agricultural village in Indang, Cavite, Philippines</article-title>. <source>Phillipp J Microbiol Infect Dis</source>. (<year>1998</year>) <volume>27</volume>:<fpage>93</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thein</surname><given-names>S</given-names></name><name><surname>Linn</surname><given-names>LM</given-names></name><name><surname>Aaskov</surname><given-names>J</given-names></name><name><surname>Aung</surname><given-names>M</given-names></name><name><surname>Aye</surname><given-names>M</given-names></name><name><surname>Zaw</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Development of a simple indirect enzyme-linked immunosorbent assay for the detection of immunoglobulin M antibody in serum from patients following an outbreak of chikungunya virus infection in Yangon, Myanmar</article-title>. <source>Trans R Soc Trop Med Hygiene</source>. (<year>1992</year>) <volume>86</volume>:<fpage>438</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/0035-9203(92)90260-J</pub-id><?supplied-pmid 1332222?><pub-id pub-id-type="pmid">1332222</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sergon</surname><given-names>K</given-names></name><name><surname>Njuguna</surname><given-names>C</given-names></name><name><surname>Kalani</surname><given-names>R</given-names></name><name><surname>Ofula</surname><given-names>V</given-names></name><name><surname>Onyango</surname><given-names>C</given-names></name><name><surname>Konongoi</surname><given-names>LS</given-names></name><etal/></person-group>. <article-title>Seroprevalence of chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004</article-title>. <source>Am J Trop Med Hyg</source>. (<year>2008</year>) <volume>78</volume>:<fpage>333</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2008.78.333</pub-id><?supplied-pmid 18256441?><pub-id pub-id-type="pmid">18256441</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>LL</given-names></name><name><surname>Failloux</surname><given-names>A-B</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name></person-group>. <article-title>Chikungunya virus&#x02013;vector interactions</article-title>. <source>Viruses</source>. (<year>2014</year>) <volume>6</volume>:<fpage>4628</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.3390/v6114628</pub-id><?supplied-pmid 25421891?><pub-id pub-id-type="pmid">25421891</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>A</given-names></name><name><surname>Logue</surname><given-names>C</given-names></name></person-group>. <article-title>Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus</article-title>. <source>J Gene Virol</source>. (<year>2007</year>) <volume>88</volume>:<fpage>2363</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.82858-0</pub-id><?supplied-pmid 17698645?><pub-id pub-id-type="pmid">17698645</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Bogoch</surname><given-names>I</given-names></name><name><surname>Brownstein</surname><given-names>JS</given-names></name><name><surname>Miniota</surname><given-names>J</given-names></name><name><surname>Nicolucci</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Assessing the origin of and potential for international spread of chikungunya virus from the caribbean</article-title>. <source>PLoS Curr</source>. (<year>2014</year>) <volume>6</volume>, <fpage>1</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1371/currents.outbreaks.2134a0a7bf37fd8d388181539fea2da5</pub-id><?supplied-pmid 24944846?><pub-id pub-id-type="pmid">24944846</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>Ong</surname><given-names>EK</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>J-C</given-names></name><name><surname>Ng</surname><given-names>LF</given-names></name></person-group>. <article-title>Immuno-biology of chikungunya and implications for disease intervention</article-title>. <source>Microbes Infect Institut Pasteur</source>. (<year>2009</year>) <volume>11</volume>:<fpage>1186</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2009.09.003</pub-id><?supplied-pmid 19737625?><pub-id pub-id-type="pmid">19737625</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wauquier</surname><given-names>N</given-names></name><name><surname>Becquart</surname><given-names>P</given-names></name><name><surname>Nkoghe</surname><given-names>D</given-names></name><name><surname>Padilla</surname><given-names>C</given-names></name><name><surname>Ndjoyi-Mbiguino</surname><given-names>A</given-names></name><name><surname>Leroy</surname><given-names>EM</given-names></name></person-group>. <article-title>The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation</article-title>. <source>J Infect Dis</source>. (<year>2010</year>) <volume>204</volume>:<fpage>115</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiq006</pub-id><?supplied-pmid 21628665?><pub-id pub-id-type="pmid">21628665</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Her</surname><given-names>Z</given-names></name><name><surname>Ong</surname><given-names>EK</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Dimatatac</surname><given-names>F</given-names></name><name><surname>Kwek</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor</article-title>. <source>J Infect Dis</source>. (<year>2011</year>) <volume>203</volume>:<fpage>149</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiq042</pub-id><?supplied-pmid 21288813?><pub-id pub-id-type="pmid">21288813</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Anraku</surname><given-names>I</given-names></name><name><surname>Le</surname><given-names>TT</given-names></name><name><surname>Larcher</surname><given-names>T</given-names></name><name><surname>Major</surname><given-names>L</given-names></name><name><surname>Roques</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Chikungunya virus arthritis in adult wild-type mice</article-title>. <source>J Virol</source>. (<year>2010</year>) <volume>84</volume>:<fpage>8021</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02603-09</pub-id><?supplied-pmid 20519386?><pub-id pub-id-type="pmid">20519386</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labadie</surname><given-names>K</given-names></name><name><surname>Larcher</surname><given-names>T</given-names></name><name><surname>Joubert</surname><given-names>C</given-names></name><name><surname>Mannioui</surname><given-names>A</given-names></name><name><surname>Delache</surname><given-names>B</given-names></name><name><surname>Brochard</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages</article-title>. <source>J Clin Investig</source>. (<year>2010</year>) <volume>120</volume>:<fpage>894</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1172/JCI40104</pub-id><?supplied-pmid 20179353?><pub-id pub-id-type="pmid">20179353</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilte</surname><given-names>C</given-names></name><name><surname>Couderc</surname><given-names>T</given-names></name><name><surname>Chretien</surname><given-names>F</given-names></name><name><surname>Sourisseau</surname><given-names>M</given-names></name><name><surname>Gangneux</surname><given-names>N</given-names></name><name><surname>Guivel-Benhassine</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Type I IFN controls chikungunya virus via its action on nonhematopoietic cells</article-title>. <source>J Exp Med</source>. (<year>2010</year>) <volume>207</volume>:<fpage>429</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20090851</pub-id><?supplied-pmid 20123960?><pub-id pub-id-type="pmid">20123960</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lum</surname><given-names>F</given-names></name><name><surname>Ng</surname><given-names>LF</given-names></name></person-group>. <article-title>Cellular and molecular mechanisms of chikungunya pathogenesis</article-title>. <source>Antiviral Res</source>. (<year>2015</year>) <volume>120</volume>:<fpage>165</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.06.009</pub-id><?supplied-pmid 26092642?><pub-id pub-id-type="pmid">26092642</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>Y-H</given-names></name><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Utt</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>JJ</given-names></name><name><surname>Amrun</surname><given-names>S</given-names></name><name><surname>Bakar</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate</article-title>. <source>EMBO Mol Med</source>. (<year>2019</year>) <volume>11</volume>:<fpage>e10092</fpage>. <pub-id pub-id-type="doi">10.15252/emmm.201810092</pub-id><?supplied-pmid 31015278?><pub-id pub-id-type="pmid">31015278</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>Simarmata</surname><given-names>D</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Her</surname><given-names>Z</given-names></name><name><surname>Teng</surname><given-names>T-S</given-names></name><name><surname>Ong</surname><given-names>EK</given-names></name><etal/></person-group>. <article-title>Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection</article-title>. <source>J Infect Dis</source>. (<year>2012</year>) <volume>205</volume>:<fpage>1147</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis033</pub-id><?supplied-pmid 22389226?><pub-id pub-id-type="pmid">22389226</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>Lum</surname><given-names>F</given-names></name><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Simarmata</surname><given-names>D</given-names></name><name><surname>Harjanto</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein</article-title>. <source>EMBO Mol Med</source>. (<year>2012</year>) <volume>4</volume>:<fpage>330</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1002/emmm.201200213</pub-id><?supplied-pmid 22389221?><pub-id pub-id-type="pmid">22389221</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Simarmata</surname><given-names>D</given-names></name><name><surname>Harjanto</surname><given-names>S</given-names></name><name><surname>Teng</surname><given-names>T-S</given-names></name><name><surname>Tolou</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Longitudinal analysis of the human antibody response to chikungunya virus infection: implications for serodiagnosis and vaccine development</article-title>. <source>J Virol</source>. (<year>2012</year>) <volume>86</volume>:<fpage>13005</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01780-12</pub-id><?supplied-pmid 23015702?><pub-id pub-id-type="pmid">23015702</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Simarmata</surname><given-names>D</given-names></name><name><surname>Grand</surname><given-names>R</given-names></name><name><surname>Tolou</surname><given-names>H</given-names></name><name><surname>Merits</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Unique epitopes recognized by antibodies induced in chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development</article-title>. <source>PLoS ONE</source>. (<year>2014</year>) <volume>9</volume>:<fpage>e95647</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0095647</pub-id><?supplied-pmid 24755730?><pub-id pub-id-type="pmid">24755730</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lum</surname><given-names>F</given-names></name><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L</given-names></name><name><surname>Ng</surname><given-names>LF</given-names></name></person-group>. <article-title>An essential role of antibodies in the control of chikungunya virus infection</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>190</volume>:<fpage>6295</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1300304</pub-id><?supplied-pmid 23670192?><pub-id pub-id-type="pmid">23670192</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poo</surname><given-names>Y</given-names></name><name><surname>Nakaya</surname><given-names>H</given-names></name><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Larcher</surname><given-names>T</given-names></name><name><surname>Schroder</surname><given-names>WA</given-names></name><name><surname>Le</surname><given-names>TT</given-names></name><etal/></person-group>
<article-title>Diamond. CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis</article-title>. <source>J Virol</source>. (<year>2014</year>) <volume>88</volume>:<fpage>6862</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03364-13</pub-id><pub-id pub-id-type="pmid">24696480</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petitdemange</surname><given-names>C</given-names></name><name><surname>Wauquier</surname><given-names>N</given-names></name><name><surname>Vieillard</surname><given-names>V</given-names></name></person-group>. <article-title>Control of immunopathology during chikungunya virus infection</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2015</year>) <volume>135</volume>:<fpage>846</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2015.01.039</pub-id><?supplied-pmid 25843597?><pub-id pub-id-type="pmid">25843597</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Lum</surname><given-names>F</given-names></name><name><surname>Claser</surname><given-names>C</given-names></name><name><surname>Lulla</surname><given-names>V</given-names></name><name><surname>Lulla</surname><given-names>A</given-names></name><name><surname>Merits</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A pathogenic role for CD4<sup>+</sup> T cells during chikungunya virus infection in mice</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>190</volume>:<fpage>259</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1202177</pub-id><?supplied-pmid 23209328?><pub-id pub-id-type="pmid">23209328</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>Y-H</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Lum</surname><given-names>F</given-names></name><name><surname>Amrun</surname><given-names>S</given-names></name><name><surname>Her</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Fingolimod treatment abrogates chikungunya virus-induced arthralgia</article-title>. <source>Sci Transl Med</source>. (<year>2017</year>) <volume>9</volume>:<fpage>eaal1333</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aal1333</pub-id><?supplied-pmid 28148838?><pub-id pub-id-type="pmid">28148838</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Dias</surname><given-names>C</given-names></name><name><surname>Gois</surname><given-names>B</given-names></name><name><surname>Lima</surname><given-names>V</given-names></name><name><surname>Guerra-Gomes</surname><given-names>I</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>J</given-names></name><name><surname>de Gomes</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Human CD8 T-cell activation in acute and chronic chikungunya infection</article-title>. <source>Immunology</source>. (<year>2018</year>) <volume>155</volume>:<fpage>499</fpage>&#x02013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12992</pub-id><pub-id pub-id-type="pmid">30099739</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoarau</surname><given-names>J-J</given-names></name><name><surname>Bandjee</surname><given-names>M-C</given-names></name><name><surname>Trotot</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>T</given-names></name><name><surname>Li-Pat-Yuen</surname><given-names>G</given-names></name><name><surname>Dassa</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>184</volume>:<fpage>5914</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0900255</pub-id><?supplied-pmid 20404278?><pub-id pub-id-type="pmid">20404278</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratheek</surname><given-names>B</given-names></name><name><surname>Suryawanshi</surname><given-names>AR</given-names></name><name><surname>Chattopadhyay</surname><given-names>S</given-names></name><name><surname>Chattopadhyay</surname><given-names>S</given-names></name></person-group>. <article-title><italic>In silico</italic> analysis of MHC-I restricted epitopes of chikungunya virus proteins: implication in understanding anti-CHIKV CD8<sup>+</sup> T cell response and advancement of epitope based immunotherapy for CHIKV infection</article-title>. <source>Infect Gene Evol</source>. (<year>2015</year>) <volume>31</volume>:<fpage>118</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2015.01.017</pub-id><?supplied-pmid 25643869?><pub-id pub-id-type="pmid">25643869</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waheed</surname><given-names>Y</given-names></name><name><surname>Safi</surname><given-names>S</given-names></name><name><surname>Najmi</surname><given-names>M</given-names></name><name><surname>Aziz</surname><given-names>H</given-names></name><name><surname>Imran</surname><given-names>M</given-names></name></person-group>. <article-title>Prediction of promiscuous T cell epitopes in RNA dependent RNA polymerase of chikungunya virus</article-title>. <source>Asian Pacific J Trop Med</source>. (<year>2017</year>) <volume>10</volume>:<fpage>760</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.apjtm.2017.07.023</pub-id><?supplied-pmid 28942824?><pub-id pub-id-type="pmid">28942824</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorente</surname><given-names>E</given-names></name><name><surname>Barriga</surname><given-names>A</given-names></name><name><surname>Garc&#x000ed;a-Arriaza</surname><given-names>J</given-names></name><name><surname>Lemonnier</surname><given-names>FA</given-names></name><name><surname>Esteban</surname><given-names>M</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>D</given-names></name></person-group>. <article-title>Complex antigen presentation pathway for an HLA-A<sup>*</sup>0201-restricted epitope from chikungunya 6K protein</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2017</year>) <volume>11</volume>:<fpage>e0006036</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0006036</pub-id><?supplied-pmid 29084215?><pub-id pub-id-type="pmid">29084215</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrack</surname><given-names>KS</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Homann</surname><given-names>D</given-names></name><name><surname>Morrison</surname><given-names>TE</given-names></name></person-group>. <article-title>CD8<sup>+</sup> T Cells control ross river virus infection in musculoskeletal tissues of infected mice</article-title>. <source>J Immunol</source>. (<year>2015</year>) <volume>194</volume>:<fpage>678</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1401833</pub-id><?supplied-pmid 25488988?><pub-id pub-id-type="pmid">25488988</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooke</surname><given-names>CB</given-names></name><name><surname>Deming</surname><given-names>DJ</given-names></name><name><surname>Whitmore</surname><given-names>AC</given-names></name><name><surname>White</surname><given-names>LJ</given-names></name><name><surname>Johnston</surname><given-names>RE</given-names></name></person-group>. <article-title>T cells facilitate recovery from venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody</article-title>. <source>J Virol</source>. (<year>2010</year>) <volume>84</volume>:<fpage>4556</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02545-09</pub-id><?supplied-pmid 20181704?><pub-id pub-id-type="pmid">20181704</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawman</surname><given-names>DW</given-names></name><name><surname>Stoermer</surname><given-names>KA</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Pal</surname><given-names>P</given-names></name><name><surname>Oko</surname><given-names>L</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response</article-title>. <source>J Virol</source>. (<year>2013</year>) <volume>87</volume>:<fpage>13878</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02666-13</pub-id><?supplied-pmid 24131709?><pub-id pub-id-type="pmid">24131709</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group>. <article-title>High antigen levels are the cause of T cell exhaustion during chronic viral infection</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2009</year>) <volume>106</volume>:<fpage>8623</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0809818106</pub-id><?supplied-pmid 19433785?><pub-id pub-id-type="pmid">19433785</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Kamphorst</surname><given-names>AO</given-names></name><name><surname>Im</surname><given-names>S</given-names></name><name><surname>Kissick</surname><given-names>HT</given-names></name><name><surname>Pillai</surname><given-names>RN</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions</article-title>. <source>Ann Rev Med</source>. (<year>2018</year>) <volume>69</volume>:<fpage>301</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-med-012017-043208</pub-id><?supplied-pmid 29414259?><pub-id pub-id-type="pmid">29414259</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackburn</surname><given-names>SD</given-names></name><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Haining</surname><given-names>NW</given-names></name><name><surname>Zou</surname><given-names>T</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Polley</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Coregulation of CD8<sup>+</sup> T cell exhaustion by multiple inhibitory receptors during chronic viral infection</article-title>. <source>Nat Immunol</source>. (<year>2008</year>) <volume>10</volume>:<fpage>29</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1679</pub-id><?supplied-pmid 19043418?><pub-id pub-id-type="pmid">19043418</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>NS</given-names></name><name><surname>Moebius</surname><given-names>J</given-names></name><name><surname>Pewe</surname><given-names>LL</given-names></name><name><surname>Traore</surname><given-names>B</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Tygrett</surname><given-names>LT</given-names></name><etal/></person-group>. <article-title>Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage plasmodium infection</article-title>. <source>Nat Publ Group</source>. (<year>2012</year>) <volume>13</volume>:<fpage>188</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2180</pub-id><?supplied-pmid 22157630?><pub-id pub-id-type="pmid">22157630</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karunarathne</surname><given-names>DS</given-names></name><name><surname>Horne-Debets</surname><given-names>JM</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Faleiro</surname><given-names>R</given-names></name><name><surname>Leow</surname><given-names>C</given-names></name><name><surname>Amante</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Programmed death-1 ligand 2-mediated regulation of the PD-L1 to PD-1 axis is essential for establishing CD4<sup>+</sup> T cell immunity</article-title>. <source>Immunity</source>. (<year>2016</year>) <volume>45</volume>:<fpage>333</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2016.07.017</pub-id><?supplied-pmid 27533014?><pub-id pub-id-type="pmid">27533014</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horne-Debets</surname><given-names>JM</given-names></name><name><surname>Faleiro</surname><given-names>R</given-names></name><name><surname>Karunarathne</surname><given-names>DS</given-names></name><name><surname>Liu</surname><given-names>XQ</given-names></name><name><surname>Lineburg</surname><given-names>KE</given-names></name><name><surname>Poh</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>PD-1 Dependent exhaustion of CD8<sup>+</sup> T cells drives chronic malaria</article-title>. <source>Cell Rep</source>. (<year>2013</year>) <volume>5</volume>:<fpage>1204</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.002</pub-id><?supplied-pmid 24316071?><pub-id pub-id-type="pmid">24316071</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horne-Debets</surname><given-names>JM</given-names></name><name><surname>Karunarathne</surname><given-names>DS</given-names></name><name><surname>Faleiro</surname><given-names>RJ</given-names></name><name><surname>Poh</surname><given-names>C</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L</given-names></name><name><surname>Wykes</surname><given-names>MN</given-names></name></person-group>. <article-title>Mice lacking programmed cell death-1 show a role for CD8(+) T cells in long-term immunity against blood-stage malaria</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<fpage>26210</fpage>. <pub-id pub-id-type="doi">10.1038/srep26210</pub-id><?supplied-pmid 27217330?><pub-id pub-id-type="pmid">27217330</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Howland</surname><given-names>SW</given-names></name><name><surname>Claser</surname><given-names>C</given-names></name><name><surname>Gun</surname><given-names>S</given-names></name><name><surname>Poh</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name><etal/></person-group>. <article-title>Co-infection with chikungunya virus alters trafficking of pathogenic CD8<sup>+</sup> T cells into the brain and prevents plasmodium-induced neuropathology</article-title>. <source>EMBO Mol Med</source>. (<year>2018</year>) <volume>10</volume>:<fpage>121</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.15252/emmm.201707885</pub-id><?supplied-pmid 29113976?><pub-id pub-id-type="pmid">29113976</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miner</surname><given-names>JJ</given-names></name><name><surname>Cook</surname><given-names>LE</given-names></name><name><surname>Hong</surname><given-names>JP</given-names></name><name><surname>ith</surname><given-names>A</given-names></name><name><surname>Richner</surname><given-names>JM</given-names></name><name><surname>imak</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis</article-title>. <source>Sci Transl Med</source>. (<year>2017</year>) <volume>9</volume>:<fpage>eaah3438</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aah3438</pub-id><?supplied-pmid 28148840?><pub-id pub-id-type="pmid">28148840</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carissimo</surname><given-names>G</given-names></name><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>Y-H</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Torres-Ruesta</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Viperin controls chikungunya virus&#x02013;specific pathogenic T cell IFN&#x003b3; Th1 stimulation in mice</article-title>. <source>Life Sci Alliance</source>. (<year>2019</year>) <volume>2</volume>:<fpage>e201900298</fpage>. <pub-id pub-id-type="doi">10.26508/lsa.201900298</pub-id><?supplied-pmid 30665948?><pub-id pub-id-type="pmid">30665948</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fros</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Prow</surname><given-names>NA</given-names></name><name><surname>Geertsema</surname><given-names>C</given-names></name><name><surname>Ligtenberg</surname><given-names>M</given-names></name><name><surname>Vanlandingham</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling</article-title>. <source>J Virol</source>. (<year>2010</year>) <volume>84</volume>:<fpage>10877</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00949-10</pub-id><?supplied-pmid 20686047?><pub-id pub-id-type="pmid">20686047</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Teo</surname><given-names>T</given-names></name><name><surname>Her</surname><given-names>Z</given-names></name><name><surname>Lum</surname><given-names>F</given-names></name><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>Haase</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Expanding regulatory T cells alleviates chikungunya virus-induced pathology in mice</article-title>. <source>J Virol</source>. (<year>2015</year>) <volume>89</volume>:<fpage>7893</fpage>&#x02013;<lpage>904</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00998-15</pub-id><?supplied-pmid 25995249?><pub-id pub-id-type="pmid">25995249</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>S</given-names></name><name><surname>Ganu</surname><given-names>M</given-names></name><name><surname>Jayawant</surname><given-names>P</given-names></name><name><surname>Thanapati</surname><given-names>S</given-names></name><name><surname>Ganu</surname><given-names>A</given-names></name><name><surname>Tripathy</surname><given-names>A</given-names></name></person-group>. <article-title>Regulatory T cells and IL-10 as modulators of chikungunya disease outcome: a preliminary study</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. (<year>2017</year>) <volume>36</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-017-3087-4</pub-id><?supplied-pmid 28840350?><pub-id pub-id-type="pmid">27649698</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanapati</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Tripathy</surname><given-names>AS</given-names></name></person-group>. <article-title>Phenotypic and functional analyses of NK and NKT-like populations during the early stages of chikungunya infection</article-title>. <source>Front Microbiol</source>. (<year>2015</year>) <volume>6</volume>:<fpage>23</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.00895</pub-id><?supplied-pmid 26388848?><pub-id pub-id-type="pmid">25699024</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanapati</surname><given-names>S</given-names></name><name><surname>Ganu</surname><given-names>MA</given-names></name><name><surname>Tripathy</surname><given-names>AS</given-names></name></person-group>. <article-title>Differential inhibitory and activating NK cell receptor levels and NK/NKT-like cell functionality in chronic and recovered stages of chikungunya</article-title>. <source>PLoS ONE</source>. (<year>2017</year>) <volume>12</volume>:<fpage>e0188342</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0188342</pub-id><?supplied-pmid 29182664?><pub-id pub-id-type="pmid">29182664</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wingender</surname><given-names>G</given-names></name><name><surname>Stepniak</surname><given-names>D</given-names></name><name><surname>Krebs</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>McBride</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Intestinal microbes affect phenotypes and functions of invariant natural killer T cells in mice</article-title>. <source>Gastroenterology</source>. (<year>2012</year>) <volume>143</volume>:<fpage>418</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2012.04.017</pub-id><?supplied-pmid 22522092?><pub-id pub-id-type="pmid">22522092</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Soler</surname><given-names>D</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group>
<article-title>Differential chemokine responses and homing patterns of murine TCR&#x003b1;&#x003b2; NKT cell subsets</article-title>. <source>J Immunol</source>. (<year>2003</year>) <volume>171</volume>:<fpage>2960</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.171.6.2960</pub-id><pub-id pub-id-type="pmid">12960320</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Johnston</surname><given-names>B</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group>
<article-title>Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V&#x003b1;24<sup>+</sup>V&#x003b2;11<sup>+</sup> NKT cell subsets with distinct cytokine-producing capacity</article-title>. <source>Blood</source>. (<year>2002</year>) <volume>100</volume>:<fpage>11</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2001-12-0196</pub-id><pub-id pub-id-type="pmid">12070001</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>KM</given-names></name><name><surname>Ferris</surname><given-names>MT</given-names></name><name><surname>Whitmore</surname><given-names>AC</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Thurlow</surname><given-names>LR</given-names></name><name><surname>McGee</surname><given-names>CE</given-names></name><etal/></person-group>. <article-title>&#x003b3;&#x003b4; T cells play a protective role in chikungunya virus-induced disease</article-title>. <source>J Virol</source>. (<year>2016</year>) <volume>90</volume>:<fpage>433</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02159-15</pub-id><?supplied-pmid 26491151?><pub-id pub-id-type="pmid">26491151</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halleng&#x000e4;rd</surname><given-names>D</given-names></name><name><surname>Lum</surname><given-names>F</given-names></name><name><surname>K&#x000fc;mmerer</surname><given-names>BM</given-names></name><name><surname>Lulla</surname><given-names>A</given-names></name><name><surname>Lulla</surname><given-names>V</given-names></name><name><surname>Garc&#x000ed;a-Arriaza</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Prime-boost immunization strategies against chikungunya virus</article-title>. <source>J Virol</source>. (<year>2014</year>) <volume>88</volume>:<fpage>13333</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01926-14</pub-id><?supplied-pmid 25210177?><pub-id pub-id-type="pmid">25210177</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weger-Lucarelli</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Aliota</surname><given-names>MT</given-names></name><name><surname>Partidos</surname><given-names>CD</given-names></name><name><surname>Osorio</surname><given-names>JE</given-names></name></person-group>. <article-title>A novel MVA vectored chikungunya virus vaccine elicits protective immunity in mice</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2014</year>) <volume>8</volume>:<fpage>e2970</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0002970</pub-id><?supplied-pmid 25058320?><pub-id pub-id-type="pmid">25058320</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ar&#x000e9;valo</surname><given-names>MT</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Ross</surname><given-names>TM</given-names></name></person-group>. <article-title>Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2019</year>) <volume>13</volume>:<fpage>e0007316</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0007316</pub-id><?supplied-pmid 31026260?><pub-id pub-id-type="pmid">31026260</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reisinger</surname><given-names>EC</given-names></name><name><surname>Tschismarov</surname><given-names>R</given-names></name><name><surname>Beubler</surname><given-names>E</given-names></name><name><surname>Wiedermann</surname><given-names>U</given-names></name><name><surname>Firbas</surname><given-names>C</given-names></name><name><surname>Loebermann</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial</article-title>. <source>Lancet</source>. (<year>2018</year>) <volume>392</volume>:<fpage>2718</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32488-7</pub-id><?supplied-pmid 30409443?><pub-id pub-id-type="pmid">30409443</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>C-L</given-names></name><name><surname>Sam</surname><given-names>I-C</given-names></name><name><surname>Merits</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>Y-F</given-names></name></person-group>. <article-title>Antigenic variation of East/Central/South African and Asian chikungunya virus genotypes in neutralization by immune sera</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2016</year>) <volume>10</volume>:<fpage>e0004960</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0004960</pub-id><?supplied-pmid 27571254?><pub-id pub-id-type="pmid">27571254</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorchakov</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Leal</surname><given-names>G</given-names></name><name><surname>Forrester</surname><given-names>NL</given-names></name><name><surname>Plante</surname><given-names>K</given-names></name><name><surname>Rossi</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein</article-title>. <source>J Virol</source>. (<year>2012</year>) <volume>86</volume>:<fpage>6084</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06449-11</pub-id><?supplied-pmid 22457519?><pub-id pub-id-type="pmid">22457519</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>PL</given-names></name><name><surname>Kochin</surname><given-names>BF</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Antia</surname><given-names>R</given-names></name></person-group>. <article-title>How do antigenically varying pathogens avoid cross-reactive responses to invariant antigens?</article-title>
<source>Proc R Soc B Biol Sci</source>. (<year>2012</year>) <volume>279</volume>:<fpage>2777</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1098/rspb.2012.0005</pub-id><?supplied-pmid 22438498?><pub-id pub-id-type="pmid">22438498</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deitsch</surname><given-names>KW</given-names></name><name><surname>Lukehart</surname><given-names>SA</given-names></name><name><surname>Stringer</surname><given-names>JR</given-names></name></person-group>. <article-title>Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens</article-title>. <source>Nat Rev Microbiol</source>. (<year>2009</year>) <volume>7</volume>:<fpage>493</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2145</pub-id><?supplied-pmid 19503065?><pub-id pub-id-type="pmid">19503065</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westernberg</surname><given-names>L</given-names></name><name><surname>Schulten</surname><given-names>V</given-names></name><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Natali</surname><given-names>S</given-names></name><name><surname>Tripple</surname><given-names>V</given-names></name><name><surname>McKinney</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>T-cell epitope conservation across allergen species is a major determinant of immunogenicity</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2016</year>) <volume>138</volume>:<fpage>571</fpage>&#x02013;<lpage>8.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2015.11.034</pub-id><?supplied-pmid 26883464?><pub-id pub-id-type="pmid">26883464</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z-R</given-names></name><name><surname>Zarnitsyna</surname><given-names>VI</given-names></name><name><surname>Lowen</surname><given-names>AC</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Koelle</surname><given-names>K</given-names></name><name><surname>Kohlmeier</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Why are CD8 T cell epitopes of human influenza a virus conserved?</article-title>
<source>J Virol</source>. (<year>2019</year>) <volume>93</volume>:<fpage>e01534</fpage>-<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01534-18</pub-id><?supplied-pmid 30626684?><pub-id pub-id-type="pmid">30626684</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <article-title>Tissue-resident memory T cells</article-title>. <source>Immunol Rev</source>. (<year>2013</year>) <volume>255</volume>:<fpage>165</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12087</pub-id><?supplied-pmid 23947354?><pub-id pub-id-type="pmid">23947354</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Mackay</surname><given-names>LK</given-names></name></person-group>. <article-title>Tissue-resident memory T cells: local specialists in immune defence</article-title>. <source>Nat Rev Immunol</source>. (<year>2016</year>) <volume>16</volume>:<fpage>79</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2015.3</pub-id><?supplied-pmid 26688350?><pub-id pub-id-type="pmid">26688350</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauley</surname><given-names>L</given-names></name><name><surname>Lefran&#x000e7;ois</surname><given-names>L</given-names></name></person-group>. <article-title>Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells</article-title>. <source>Mucosal Immunol</source>. (<year>2013</year>) <volume>6</volume>:<fpage>14</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/mi.2012.96</pub-id><?supplied-pmid 23131785?><pub-id pub-id-type="pmid">23131785</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Kupper</surname><given-names>TS</given-names></name></person-group>. <article-title>The emerging role of resident memory T cells in protective immunity and inflammatory disease</article-title>. <source>Nat Med</source>. (<year>2015</year>) <volume>21</volume>:<fpage>688</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3883</pub-id><?supplied-pmid 26121195?><pub-id pub-id-type="pmid">26121195</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Gebhardt</surname><given-names>T</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name></person-group>. <article-title>Memory T cell subsets, migration patterns, and tissue residence</article-title>. <source>Ann Rev Immunol</source>. (<year>2013</year>) <volume>31</volume>:<fpage>137</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095954</pub-id><?supplied-pmid 23215646?><pub-id pub-id-type="pmid">23215646</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauvau</surname><given-names>G</given-names></name><name><surname>Boutet</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name><name><surname>Chin</surname><given-names>S</given-names></name><name><surname>Chorro</surname><given-names>L</given-names></name></person-group>. <article-title>Memory CD8(+) T Cells: innate-like sensors and orchestrators of protection</article-title>. <source>Trends Immunol</source>. (<year>2016</year>) <volume>37</volume>:<fpage>375</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2016.04.001</pub-id><?supplied-pmid 27131432?><pub-id pub-id-type="pmid">27131432</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <article-title>A vaccine strategy that protects against genital herpes by establishing local memory T cells</article-title>. <source>Nature</source>. (<year>2012</year>) <volume>491</volume>:<fpage>463</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature11522</pub-id><?supplied-pmid 23075848?><pub-id pub-id-type="pmid">23075848</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Prier</surname><given-names>JE</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Gebhardt</surname><given-names>T</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Mackay</surname><given-names>LK</given-names></name></person-group>. <article-title>Cutting edge: tissue-resident memory T Cells generated by multiple immunizations or localized deposition provide enhanced immunity</article-title>. <source>J Immunol</source>. (<year>2017</year>) <volume>198</volume>:<fpage>2233</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1601367</pub-id><?supplied-pmid 28159905?><pub-id pub-id-type="pmid">28159905</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000e1;lvez-Cancino</surname><given-names>F</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>E</given-names></name><name><surname>Menares</surname><given-names>E</given-names></name><name><surname>D&#x000ed;az</surname><given-names>X</given-names></name><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>C&#x000e1;ceres</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Vaccination-induced skin-resident memory CD8<sup>+</sup>T cells mediate strong protection against cutaneous melanoma</article-title>. <source>Oncoimmunology</source>. (<year>2018</year>) <volume>7</volume>:<fpage>e1442163</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2018.1442163</pub-id><?supplied-pmid 29900048?><pub-id pub-id-type="pmid">29900048</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Fuhlbrigge</surname><given-names>RC</given-names></name><name><surname>Kupper</surname><given-names>TS</given-names></name></person-group>
<article-title>Skin infection generates non-migratory memory CD8<sup>+</sup> T<sub>RM</sub> cells providing global skin immunity</article-title>. <source>Nature</source>. (<year>2012</year>) <volume>483</volume>:<fpage>227</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/nature10851</pub-id><pub-id pub-id-type="pmid">22388819</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaide</surname><given-names>O</given-names></name><name><surname>Emerson</surname><given-names>RO</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Gulati</surname><given-names>N</given-names></name><name><surname>Nizza</surname><given-names>S</given-names></name><name><surname>Desmarais</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Common clonal origin of central and resident memory T cells following skin immunization</article-title>. <source>Nat Med</source>. (<year>2015</year>) <volume>21</volume>:<fpage>647</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3860</pub-id><?supplied-pmid 25962122?><pub-id pub-id-type="pmid">25962122</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>BF</given-names></name><name><surname>Murphy</surname><given-names>J-E</given-names></name><name><surname>Kupper</surname><given-names>TS</given-names></name><name><surname>Fuhlbrigge</surname><given-names>RC</given-names></name></person-group>. <article-title>E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system</article-title>. <source>J Immunol</source>. (<year>2004</year>) <volume>172</volume>:<fpage>1575</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.172.3.1575</pub-id><?supplied-pmid 14734737?><pub-id pub-id-type="pmid">14734737</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Dubin</surname><given-names>K</given-names></name><name><surname>Athale</surname><given-names>SK</given-names></name><name><surname>Kupper</surname><given-names>TS</given-names></name></person-group>. <article-title>Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell&#x02013;mediated immunity</article-title>. <source>Nat Med</source>. (<year>2010</year>) <volume>16</volume>:<fpage>224</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2078</pub-id><?supplied-pmid 20081864?><pub-id pub-id-type="pmid">20081864</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Johnston</surname><given-names>C</given-names></name><name><surname>Phasouk</surname><given-names>K</given-names></name><name><surname>Kask</surname><given-names>AS</given-names></name><name><surname>Klock</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Immune surveillance by CD8&#x003b1;&#x003b1;<sup>+</sup> skin-resident T cells in human herpes virus infection</article-title>. <source>Nature</source>. (<year>2013</year>) <volume>497</volume>:<fpage>494</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature12110</pub-id><?supplied-pmid 23657257?><pub-id pub-id-type="pmid">23657257</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>SJ</given-names></name><name><surname>Carlson</surname><given-names>CJ</given-names></name><name><surname>Mordecai</surname><given-names>EA</given-names></name><name><surname>Johnson</surname><given-names>LR</given-names></name></person-group>. <article-title>Global expansion and redistribution of Aedes-borne virus transmission risk with climate change</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2019</year>) <volume>13</volume>:<fpage>e0007213</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0007213</pub-id><?supplied-pmid 30921321?><pub-id pub-id-type="pmid">30921321</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>E</given-names></name><name><surname>Levinson</surname><given-names>R</given-names></name><name><surname>Rice</surname><given-names>C</given-names></name><name><surname>Dalrymple</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>J</given-names></name></person-group>. <article-title>Nonstructural proteins nsP3 and nsP4 of ross river and o'nyong-nyong viruses: sequence and comparison with those of other alphaviruses</article-title>. <source>Virology</source>. (<year>1988</year>) <volume>164</volume>:<fpage>265</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/0042-6822(88)90644-7</pub-id><?supplied-pmid 2834873?><pub-id pub-id-type="pmid">2834873</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JL</given-names></name><name><surname>Pugh</surname><given-names>CL</given-names></name><name><surname>Cisney</surname><given-names>ED</given-names></name><name><surname>Keasey</surname><given-names>SL</given-names></name><name><surname>Guevara</surname><given-names>C</given-names></name><name><surname>Ampuero</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>Human antibody responses to emerging mayaro virus and cocirculating alphavirus infections examined by using structural proteins from nine new and old world lineages</article-title>. <source>mSphere</source>. (<year>2018</year>) <volume>3</volume>:<fpage>e00003</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/mSphere.00003-18</pub-id><?supplied-pmid 29577083?><pub-id pub-id-type="pmid">29577083</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;tte</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>McInerney</surname><given-names>G</given-names></name></person-group>. <article-title>The enigmatic alphavirus non-structural protein 3 (nsP3) revealing its secrets at last</article-title>. <source>Viruses</source>. (<year>2018</year>) <volume>10</volume>:<fpage>105</fpage>. <pub-id pub-id-type="doi">10.3390/v10030105</pub-id><?supplied-pmid 29495654?><pub-id pub-id-type="pmid">29495654</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>G</given-names></name><name><surname>Yost</surname><given-names>SA</given-names></name><name><surname>Miller</surname><given-names>MT</given-names></name><name><surname>Elrod</surname><given-names>EJ</given-names></name><name><surname>Grakoui</surname><given-names>A</given-names></name><name><surname>Marcotrigiano</surname><given-names>J</given-names></name></person-group>. <article-title>Structural and functional insights into alphavirus polyproteinprocessing and pathogenesis</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2012</year>) <volume>109</volume>:<fpage>16534</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1210418109</pub-id><?supplied-pmid 23010928?><pub-id pub-id-type="pmid">23010928</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malet</surname><given-names>H</given-names></name><name><surname>Coutard</surname><given-names>B</given-names></name><name><surname>Jamal</surname><given-names>S</given-names></name><name><surname>Dutartre</surname><given-names>H</given-names></name><name><surname>Papageorgiou</surname><given-names>N</given-names></name><name><surname>Neuvonen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The crystal structures of chikungunya and venezuelan equine encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket</article-title>. <source>J Virol</source>. (<year>2009</year>) <volume>83</volume>:<fpage>6534</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00189-09</pub-id><?supplied-pmid 19386706?><pub-id pub-id-type="pmid">19386706</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roundy</surname><given-names>CM</given-names></name><name><surname>Azar</surname><given-names>SR</given-names></name><name><surname>Rossi</surname><given-names>SL</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name><name><surname>Vasilakis</surname><given-names>N</given-names></name></person-group>
<article-title>Chapter four insect-specific viruses a historical overview and recent developments</article-title>. <source>Adv Virus Res</source>. (<year>2017</year>) <volume>98</volume>:<fpage>119</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/bs.aivir.2016.10.001</pub-id><pub-id pub-id-type="pmid">28433051</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>A</given-names></name><name><surname>Brault</surname><given-names>A</given-names></name><name><surname>Shirako</surname><given-names>Y</given-names></name><name><surname>Strauss</surname><given-names>E</given-names></name><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Strauss</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Evolutionary relationships and systematics of the alphaviruses</article-title>. <source>J Virol</source>. (<year>2001</year>) <volume>75</volume>:<fpage>10118</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.75.21.10118-10131.2001</pub-id><?supplied-pmid 11581380?><pub-id pub-id-type="pmid">11581380</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Lam</surname><given-names>T</given-names></name><name><surname>Heberlein-Larson</surname><given-names>LA</given-names></name><name><surname>Smole</surname><given-names>SC</given-names></name><name><surname>Auguste</surname><given-names>AJ</given-names></name><name><surname>Hennigan</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Large-scale complete-genome sequencing and phylodynamic analysis of eastern equine encephalitis virus reveals source-sink transmission dynamics in the United States</article-title>. <source>J Virol</source>. (<year>2018</year>) <volume>92</volume>:<fpage>10118</fpage>. <pub-id pub-id-type="doi">10.1128/JVI.00074-18</pub-id><?supplied-pmid 29618651?><pub-id pub-id-type="pmid">29618651</pub-id></mixed-citation></ref></ref-list></back></article>